Jason Liebowitz, MD, FACR, an assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons. He completed undergraduate studies at Johns Hopkins University, Baltimore, where he was inducted into Phi Beta Kappa. He attended medical school at Johns Hopkins School of Medicine and completed his Internal Medicine residency at Johns Hopkins Bayview Medical Center, where he served as chief resident. He completed his rheumatology fellowship at Johns Hopkins Hospital and was honored with the 2019 Distinguished Fellow Award from the American College of Rheumatology. His research and writings have been published in The New England Journal of Medicine, JAMA, JAMA Internal Medicine, Arthritis Care and Research and The Journal of Graduate Medical Education, among other journals. He participated in fellowships with the American Federation for Aging Research (Medical Student Training in Aging Research), the American Austrian Foundation (Max Kade Clinical Clerkship in Vienna, Austria), and the fellowships at Auschwitz for the Study of Professional Ethics (through Yale School of Medicine). He is a co-editor of the textbook Clinical Innovation in Rheumatology: Past, Present, and Future, a co-editor of the book Masterclass in Medicine: Lessons from the Experts, and a co-editor of the textbook series Interdisciplinary Rheumatology.
PHILADELPHIA—William “Bill” R. Palmer, MD, MACR, was the first board-certified rheumatologist in Omaha, Neb., where he spent his entire 43-year clinical career and established himself as a great clinician, mentor and educator. Although Dr. Palmer passed away from metastatic thyroid cancer in August 2021, his memory lives on through his physician colleagues and at ACR…
PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…
PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…
PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…
PHILADELPHIA—The term autoinflammatory syndrome was coined by Daniel L. Kastner, MD, PhD, National Institutes of Health (NIH), Bethesda, Md., not long after he discovered that mutations in the gene MEFV, which codes for the protein pyrin, are responsible for familial Mediterranean fever (FMF).1 Early on, the term was meant to signify monogenic conditions in which…
Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Eric L. Matteson, MD, MPH,…
Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Gary Hoffman, MD, MS, MACR,…
The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.
Brendan Antiochos, MD, provided a timely update on research and treatments related to vasculitis, addressing treatments for ANCA-associated vasculitis and giant cell arteritis, COVID-19 vaccination and more.
Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.